Bausch + Lomb Co. (NYSE:BLCO) Shares Acquired by State Street Corp

State Street Corp lifted its position in Bausch + Lomb Co. (NYSE:BLCO) by 5.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,450 shares of the company’s stock after acquiring an additional 1,510 shares during the period. State Street Corp’s holdings in Bausch + Lomb were worth $549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. HighTower Advisors LLC lifted its stake in Bausch + Lomb by 14.7% in the 3rd quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock worth $476,000 after purchasing an additional 3,164 shares in the last quarter. Renaissance Capital LLC grew its holdings in shares of Bausch + Lomb by 20.0% in the third quarter. Renaissance Capital LLC now owns 43,560 shares of the company’s stock valued at $840,000 after purchasing an additional 7,274 shares during the period. Squarepoint Ops LLC acquired a new stake in Bausch + Lomb during the second quarter worth about $173,000. Charles Schwab Investment Management Inc. increased its position in Bausch + Lomb by 80.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 29,755 shares of the company’s stock worth $576,000 after purchasing an additional 13,302 shares during the last quarter. Finally, Polar Asset Management Partners Inc. acquired a new position in Bausch + Lomb in the 3rd quarter valued at about $289,000. 11.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on BLCO shares. Royal Bank of Canada raised their price target on shares of Bausch + Lomb from $20.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, October 22nd. Citigroup cut Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $24.00 to $22.00 in a report on Wednesday, December 11th. Morgan Stanley cut shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Bausch + Lomb in a report on Thursday, December 12th. Finally, Evercore ISI upgraded shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $19.00 to $25.00 in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bausch + Lomb presently has an average rating of “Hold” and an average target price of $20.58.

Bausch + Lomb Trading Down 1.4 %

NYSE:BLCO opened at $17.74 on Friday. The stock has a fifty day moving average price of $19.28 and a 200 day moving average price of $17.80. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Bausch + Lomb Co. has a 12-month low of $13.16 and a 12-month high of $21.69. The firm has a market cap of $6.25 billion, a PE ratio of -16.90, a price-to-earnings-growth ratio of 1.74 and a beta of 0.43.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the company posted $0.22 earnings per share. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. Sell-side analysts anticipate that Bausch + Lomb Co. will post 0.6 earnings per share for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.